Log in

NASDAQ:GLMD - Galmed Pharmaceuticals Stock Price, Forecast & News

+0.20 (+3.57 %)
(As of 01/29/2020 02:26 AM ET)
Today's Range
Now: $5.81
50-Day Range
MA: $6.05
52-Week Range
Now: $5.81
Volume60,248 shs
Average Volume84,564 shs
Market Capitalization$122.11 million
P/E RatioN/A
Dividend YieldN/A
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:GLMD



Sales & Book Value

Annual Sales$2.04 million
Book Value$4.18 per share


Net Income$-9,860,000.00


Market Cap$122.11 million
Next Earnings Date3/11/2020 (Estimated)

Receive GLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.

Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) posted its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.11. View Galmed Pharmaceuticals' Earnings History.

When is Galmed Pharmaceuticals' next earnings date?

Galmed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Galmed Pharmaceuticals.

What price target have analysts set for GLMD?

5 equities research analysts have issued 12-month price objectives for Galmed Pharmaceuticals' stock. Their forecasts range from $10.00 to $59.00. On average, they expect Galmed Pharmaceuticals' stock price to reach $30.50 in the next year. This suggests a possible upside of 425.0% from the stock's current price. View Analyst Price Targets for Galmed Pharmaceuticals.

What is the consensus analysts' recommendation for Galmed Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galmed Pharmaceuticals.

What are Wall Street analysts saying about Galmed Pharmaceuticals stock?

Here are some recent quotes from research analysts about Galmed Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. " (1/14/2020)
  • 2. Maxim Group analysts commented, "Galmed reported 2Q19 with a net loss of ($4.2M) and ended the period with $83.6M in cash." (8/6/2019)

Has Galmed Pharmaceuticals been receiving favorable news coverage?

Headlines about GLMD stock have been trending positive on Wednesday, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Galmed Pharmaceuticals earned a daily sentiment score of 2.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Galmed Pharmaceuticals.

Are investors shorting Galmed Pharmaceuticals?

Galmed Pharmaceuticals saw a increase in short interest in December. As of December 13th, there was short interest totalling 465,500 shares, an increase of 6.1% from the November 28th total of 438,700 shares. Based on an average daily trading volume, of 114,900 shares, the short-interest ratio is currently 4.1 days. Currently, 3.2% of the company's shares are short sold. View Galmed Pharmaceuticals' Current Options Chain.

Who are some of Galmed Pharmaceuticals' key competitors?

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include Opko Health (OPK), Viking Therapeutics (VKTX), Rite Aid (RAD), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), Portola Pharmaceuticals (PTLA), Immunomedics (IMMU), Micron Technology (MU), Verastem (VSTM) and NVIDIA (NVDA).

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the folowing people:
  • Mr. Allen Baharaff, Chairman, CEO & Pres (Age 54)
  • Mr. Yohai Stenzler, CFO & Controller (Age 36)
  • Mr. Guy Nehemya, Chief Operating Officer (Age 34)
  • Dr. Liat Hayardeny, Chief Scientific Officer (Age 52)
  • Dr. Tali Gorfine, Chief Medical Officer (Age 49)

Who are Galmed Pharmaceuticals' major shareholders?

Galmed Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include P.A.W. Capital Corp (0.48%).

Which institutional investors are buying Galmed Pharmaceuticals stock?

GLMD stock was purchased by a variety of institutional investors in the last quarter, including P.A.W. Capital Corp.

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $5.81.

How big of a company is Galmed Pharmaceuticals?

Galmed Pharmaceuticals has a market capitalization of $122.11 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-9,860,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.View Additional Information About Galmed Pharmaceuticals.

What is Galmed Pharmaceuticals' official website?

The official website for Galmed Pharmaceuticals is http://www.galmedpharma.com/.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448.

MarketBeat Community Rating for Galmed Pharmaceuticals (NASDAQ GLMD)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  402 (Vote Outperform)
Underperform Votes:  215 (Vote Underperform)
Total Votes:  617
MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote "Outperform" if you believe GLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel